Cargando…
Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction
Aim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD). Materials and Methods: A total of 48 patients with grade 2–3 AH and HHD at t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358430/ https://www.ncbi.nlm.nih.gov/pubmed/32733920 http://dx.doi.org/10.3389/fcvm.2020.00104 |
_version_ | 1783558848657752064 |
---|---|
author | Koval, Sergiy M. Snihurska, Iryna O. Yushko, Kostiantyn O. Mysnychenko, Olga V. Penkova, Marina Yu. Lytvynova, Olga M. Berezin, Alexander E. Lytvynov, Vadym S. |
author_facet | Koval, Sergiy M. Snihurska, Iryna O. Yushko, Kostiantyn O. Mysnychenko, Olga V. Penkova, Marina Yu. Lytvynova, Olga M. Berezin, Alexander E. Lytvynov, Vadym S. |
author_sort | Koval, Sergiy M. |
collection | PubMed |
description | Aim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD). Materials and Methods: A total of 48 patients with grade 2–3 AH and HHD at the age of 52.23 ± 7.26 (23 patients had LV DD [main group] and 25 patients had normal LV diastolic function [comparison group]) and 21 practically healthy individuals of comparable gender and age were examined. Diagnosis of AH and HHD was carried out according to the 2018 ESC/ESH recommendations. LV DD was determined according to the 2016 ASE/EACVI recommendations. Plasma microRNA-133a level was obtained by polymerase chain reaction using the CFX96 Touch System (BioRad), ≪TaqMan microRNA Assay≫ and ≪TaqMan® Universal PCR Master Mix≫ reagent kits (Thermo Fisher Scientific, USA). Results: We have found that in patients from the main and comparison groups plasma microRNA-133a levels were significantly lower than in practically healthy individuals (0.094 [0.067, 0.147]) and (0.182 [0.102, 0.301]) vs. (0.382 [0.198,0.474]), p = 0.002 and p = 0.04, respectively. In all this among patients with AH, HHD, and LV DD, plasma microRNA-133a levels were significantly lower than in patients with AH, HHD, and normal diastolic function (p = 0.03). In the main and comparison groups there was a statistically significant negative relationship between plasma microRNA-133a level and left ventricular mass index (LVMI) (R = −0.40, p = 0.003 and R = −0.35, p = 0.04, respectively). Conclusions: The findings suggest the significant role of decreased microRNA-133a levels in blood plasma of patients with AH in the pathogenesis and development of both HHD and LV DD. |
format | Online Article Text |
id | pubmed-7358430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73584302020-07-29 Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction Koval, Sergiy M. Snihurska, Iryna O. Yushko, Kostiantyn O. Mysnychenko, Olga V. Penkova, Marina Yu. Lytvynova, Olga M. Berezin, Alexander E. Lytvynov, Vadym S. Front Cardiovasc Med Cardiovascular Medicine Aim: The aim of the work was to study the circulating microRNA-133a levels in blood plasma of patients with arterial hypertension (AH), hypertensive heart disease (HHD), and left ventricular (LV) diastolic dysfunction (DD). Materials and Methods: A total of 48 patients with grade 2–3 AH and HHD at the age of 52.23 ± 7.26 (23 patients had LV DD [main group] and 25 patients had normal LV diastolic function [comparison group]) and 21 practically healthy individuals of comparable gender and age were examined. Diagnosis of AH and HHD was carried out according to the 2018 ESC/ESH recommendations. LV DD was determined according to the 2016 ASE/EACVI recommendations. Plasma microRNA-133a level was obtained by polymerase chain reaction using the CFX96 Touch System (BioRad), ≪TaqMan microRNA Assay≫ and ≪TaqMan® Universal PCR Master Mix≫ reagent kits (Thermo Fisher Scientific, USA). Results: We have found that in patients from the main and comparison groups plasma microRNA-133a levels were significantly lower than in practically healthy individuals (0.094 [0.067, 0.147]) and (0.182 [0.102, 0.301]) vs. (0.382 [0.198,0.474]), p = 0.002 and p = 0.04, respectively. In all this among patients with AH, HHD, and LV DD, plasma microRNA-133a levels were significantly lower than in patients with AH, HHD, and normal diastolic function (p = 0.03). In the main and comparison groups there was a statistically significant negative relationship between plasma microRNA-133a level and left ventricular mass index (LVMI) (R = −0.40, p = 0.003 and R = −0.35, p = 0.04, respectively). Conclusions: The findings suggest the significant role of decreased microRNA-133a levels in blood plasma of patients with AH in the pathogenesis and development of both HHD and LV DD. Frontiers Media S.A. 2020-07-07 /pmc/articles/PMC7358430/ /pubmed/32733920 http://dx.doi.org/10.3389/fcvm.2020.00104 Text en Copyright © 2020 Koval, Snihurska, Yushko, Mysnychenko, Penkova, Lytvynova, Berezin and Lytvynov. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Koval, Sergiy M. Snihurska, Iryna O. Yushko, Kostiantyn O. Mysnychenko, Olga V. Penkova, Marina Yu. Lytvynova, Olga M. Berezin, Alexander E. Lytvynov, Vadym S. Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title | Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title_full | Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title_fullStr | Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title_full_unstemmed | Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title_short | Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction |
title_sort | circulating microrna-133a in patients with arterial hypertension, hypertensive heart disease, and left ventricular diastolic dysfunction |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358430/ https://www.ncbi.nlm.nih.gov/pubmed/32733920 http://dx.doi.org/10.3389/fcvm.2020.00104 |
work_keys_str_mv | AT kovalsergiym circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT snihurskairynao circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT yushkokostiantyno circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT mysnychenkoolgav circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT penkovamarinayu circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT lytvynovaolgam circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT berezinalexandere circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction AT lytvynovvadyms circulatingmicrorna133ainpatientswitharterialhypertensionhypertensiveheartdiseaseandleftventriculardiastolicdysfunction |